BiotechTube

Entereg + Entereg + placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Laparoscopic Colonic Resection

Conditions

Laparoscopic Colonic Resection

Trial Timeline

Nov 1, 2010 → Jul 1, 2015

NCT ID
NCT01258569

About Entereg + Entereg + placebo

Entereg + Entereg + placebo is a phase 2 stage product being developed by Merck for Laparoscopic Colonic Resection. The current trial status is completed. This product is registered under clinical trial identifier NCT01258569. Target conditions include Laparoscopic Colonic Resection.

What happened to similar drugs?

3 of 6 similar drugs in Laparoscopic Colonic Resection were approved

Approved (3) Terminated (1) Active (2)
✅Rocuronium + RocuroniumMerckApproved
✅Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved
✅etoricoxib 120 mgMerckApproved
🔄SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
🔄placebo + valdecoxib + valdecoxibPfizerPhase 3
❌N1539 + N1539 + N1539 + Ketorolac Tromethamine + PlaceboAlkermesPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01258569Phase 2Completed

Competing Products

7 competing products in Laparoscopic Colonic Resection

See all competitors
ProductCompanyStageHype Score
Pudexacianinium chlorideAstellas PharmaPhase 2
35
SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
36
Rocuronium + RocuroniumMerckApproved
43
Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved
39
etoricoxib 120 mgMerckApproved
43
placebo + valdecoxib + valdecoxibPfizerPhase 3
40
N1539 + N1539 + N1539 + Ketorolac Tromethamine + PlaceboAlkermesPhase 3
29